Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

21.1%

19 terminated/withdrawn out of 90 trials

Success Rate

70.3%

-16.2% vs industry average

Late-Stage Pipeline

3%

3 trials in Phase 3/4

Results Transparency

62%

28 of 45 completed trials have results

Key Signals

17 recruiting28 with results17 terminated

Enrollment Performance

Analytics

Phase 1
44(55.0%)
Phase 2
27(33.8%)
N/A
6(7.5%)
Phase 3
3(3.8%)
80Total
Phase 1(44)
Phase 2(27)
N/A(6)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (90)

Showing 20 of 90 trials
NCT06158828Phase 1Recruiting

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Role: collaborator

NCT05536349Phase 2Recruiting

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Role: collaborator

NCT04088890Phase 1Completed

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Role: collaborator

NCT03236428Phase 2Active Not Recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Role: collaborator

NCT06071624Phase 1Recruiting

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Role: collaborator

NCT07029217Phase 3Recruiting

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

Role: collaborator

NCT02269592Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Role: collaborator

NCT06429449Phase 1Recruiting

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Role: collaborator

NCT05188170Phase 1Recruiting

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Role: collaborator

NCT04024761Phase 1Recruiting

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Role: collaborator

NCT00398177Recruiting

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

Role: collaborator

NCT06756308Phase 2Recruiting

A Study of Enasidenib in People With T-Cell Lymphoma

Role: collaborator

NCT06232655Phase 2Recruiting

Cladribine Venetoclax in Monocytic AML

Role: collaborator

NCT03803696Not ApplicableActive Not Recruiting

Multimodal Sexual Dysfunction Intervention In HCT

Role: collaborator

NCT05709912Not ApplicableActive Not Recruiting

Mobile CARE-App to Promote Coping for Caregivers of Patients Receiving Stem Cell Transplant

Role: collaborator

NCT05690971Not ApplicableActive Not Recruiting

Psychosocial Mobile App for Chronic Graft-Versus-Host Disease

Role: collaborator

NCT06916767Phase 1Recruiting

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Role: collaborator

NCT02756962Phase 2Active Not Recruiting

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Role: collaborator

NCT03016377Phase 1Active Not Recruiting

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Role: collaborator

NCT02251548Phase 2Active Not Recruiting

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Role: collaborator